The DTWD2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DTWD2 gene in the near-haploid HAP1 human cell line. This polyclonal knockout pool provides a heterogeneous population of cells harboring targeted gene disruptions, enabling loss-of-function studies without the need for single-cell cloning. By introducing targeted double-strand breaks in the DTWD2 locus, the CRISPR/Cas9 system generates a diverse array of knockout mutations across the cell population, facilitating robust functional analyses.
HAP1 is a human male fibroblast-like cell line derived from the KBM-7 chronic myeloid leukemia line. Its near-haploid karyotype, with one copy of most chromosomes, makes it an exceptionally powerful system for genetic knockout studies. Unlike diploid cells, disruption of a single allele in HAP1 cells often results in a complete loss-of-function phenotype, eliminating concerns over genetic redundancy and enabling clear interpretation of knockout effects. This characteristic, combined with its adherent growth and stable genetics, has established HAP1 as a premier model for functional genomics, high-throughput genetic screens, and mechanistic cell biology research.
DTWD2 is predicted to function as a methyltransferase that modifies mitochondrial tRNAs, a process essential for accurate mitochondrial translation. This modification is critical for the synthesis of mitochondrial-encoded subunits of respiratory chain complexes I, III, IV, and V, thereby directly linking DTWD2 activity to oxidative phosphorylation. DTWD2 likely interacts with mitochondrial ribosomal proteins and components of the tRNA methyltransferase complex to ensure proper tRNA maturation and ribosome function. While upstream regulators of DTWD2 remain unidentified, its downstream consequences impact mitochondrial protein synthesis and respiratory chain assembly, positioning it at the nexus of mitochondrial gene expression and cellular energy metabolism.
In the HAP1 cellular context, DTWD2 disruption is expected to impair mitochondrial tRNA modification, leading to defective mitochondrial translation and compromised oxidative phosphorylation. The haploid nature of HAP1 cells magnifies the phenotypic consequences of DTWD2 loss, providing an exquisitely sensitive model to dissect the molecular mechanisms of mitochondrial tRNA modification pathways. This system enables the investigation of potential mitochondrial disorders linked to tRNA modification defects and offers a platform for chemical or genetic screens targeting mitochondrial function.
Researchers can utilize this knockout model for a variety of applications, including western blotting and RT-qPCR to evaluate mitochondrial protein expression, immunofluorescence to visualize respiratory chain complex distribution, and Seahorse metabolic flux analysis or MTT assays to quantify mitochondrial respiration defects. Direct measurement of mitochondrial protein synthesis via radiolabeled methionine incorporation and tRNA modification profiling by mass spectrometry can provide detailed mechanistic insights, while sucrose gradient ribosome profiling may assess translation defects. For further details or to acquire this product, contact Ascent Research.
